# Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19

> **NCT04918927** · PHASE2 · COMPLETED · sponsor: **Coordinación de Investigación en Salud, Mexico** · enrollment: 120 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Favipiravir
- **DRUG:** Nitazoxanide
- **OTHER:** Nitazoxanide Placebo

## Key facts

- **NCT ID:** NCT04918927
- **Lead sponsor:** Coordinación de Investigación en Salud, Mexico
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-12
- **Primary completion:** 2023-03-21
- **Final completion:** 2023-03-21
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2023-03-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04918927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04918927, "Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04918927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*